机构:[1]Stanford Hosp & Clin, Div Hematol & Oncol, Stanford, CA USA;[2]Stanford Univ, Stanford Canc Inst, Stanford, CA 94305 USA;[3]Sun Yat Sen Univ, Dept Med Oncol, Collaborat Innovat Ctr Canc Med, State Key Lab Oncol South China,Canc Ctr, Guangzhou, Guangdong, Peoples R China;临床科室其他部门内科华南肿瘤学国家重点实验室中山大学肿瘤防治中心[4]Stanford Univ, Div Oncol, Dept Med, Sch Med, Stanford, CA 94305 USA;[5]Palo Alto Vet Adm Hlth Care Syst, Palo Alto, CA USA;[6]Stanford Univ, Dept Radiat Oncol, Stanford, CA 94305 USA
Introduction: Erb-b2 receptor tyrosine kinase 2 gene (ERBB2) (also called HER2) has long been recognized as an oncogenic driver in some breast and gastroesophageal cancers in which amplification of this gene confers sensitivity to treatment with Erb-b2 receptor tyrosine kinase 2 (ERBB2)-directed agents. More recently, somatic mutations in ERBB2 have been reported in 1% to 2% of patients with lung adenocarcinoma. Previous case series have suggested clinical tumor responses using antiERBB2 small molecules and antibody therapies. Methods: Here we report the outcomes of nine patients with metastatic lung adenocarcinoma with ERBB2 mutations being treated with ERBB2-targeted therapies. Results: Four of the nine patients had response to targeted therapies, with durations of response ranging from 3 to 10 months. We identified a de novo phosphatidylinositol-4,5bisphosphate 3-kinase catalytic subunit alpha gene (PIK3CA) mutation and ERBB2 copy number gain as potential resistance mechanisms. Conclusions: We showed patients with ERBB2-mutated lung adenocarcinoma can respond to targeted therapies, and we identified potential resistance mechanisms upon progression to targeted therapies. (C) 2017 International Association for the Study of Lung Cancer. Published by Elsevier Inc. All rights reserved.
基金:
Stanford Cancer Institute Cancer Center Support Grant of the National Institutes of Health [P30 CA124435]; National Cancer InstituteUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [R01CA188298]; U.S. National Institutes of Health Director's New Innovator Award Program [1-DP2-CA186569]
语种:
外文
被引次数:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2017]版:
大类|2 区医学
小类|2 区肿瘤学2 区呼吸系统
最新[2023]版:
大类|1 区医学
小类|1 区肿瘤学1 区呼吸系统
第一作者:
第一作者机构:[1]Stanford Hosp & Clin, Div Hematol & Oncol, Stanford, CA USA;
通讯作者:
通讯机构:[4]Stanford Univ, Div Oncol, Dept Med, Sch Med, Stanford, CA 94305 USA;
推荐引用方式(GB/T 7714):
Chuang Jody C.,Stehr Henning,Liang Ying,et al.ERBB2-Mutated Metastatic Non-Small Cell Lung Cancer: Response and Resistance to Targeted Therapies[J].JOURNAL OF THORACIC ONCOLOGY.2017,12(5):833-842.doi:10.1016/j.jtho.2017.01.023.
APA:
Chuang, Jody C.,Stehr, Henning,Liang, Ying,Das, Millie,Huang, Jane...&Neal, Joel W..(2017).ERBB2-Mutated Metastatic Non-Small Cell Lung Cancer: Response and Resistance to Targeted Therapies.JOURNAL OF THORACIC ONCOLOGY,12,(5)
MLA:
Chuang, Jody C.,et al."ERBB2-Mutated Metastatic Non-Small Cell Lung Cancer: Response and Resistance to Targeted Therapies".JOURNAL OF THORACIC ONCOLOGY 12..5(2017):833-842